More Access and Evidence Articles

Access and Evidence

VBCs: Are They Working?

Adam Chapman, (Dec 12, 2018)

Are value-based contracts actually improving patient access to new medicines?
Access and Evidence

Calling the Shots?

Katie Osborne, (Dec 10, 2018)

How influential are the value assessments from bodies like ICER?
Access and Evidence

Cutting Out the Middleman

Hugh Gosling, (Dec 7, 2018)

Are PBMs part of the problem or the solution?
Access and Evidence

Value-Based Contracting: Do We Have The Data?

Andy stone, (Nov 20, 2018)

Deals have been signed. Promises have been made. But are companies delivering the goods?
Access and Evidence

How To Illustrate Your RWE To Payers

Adam Chapman, (Nov 1, 2018)

Data visualization tools are demystifying real-world evidence.
Access and Evidence

American Healthcare System 1 - 0 Europe

Andy stone, (Oct 23, 2018)

When it comes to pricing and access, the European healthcare system is losing.
Access and Evidence

Working with HTAs: It’s Your Move

Ross Davies, (Oct 16, 2018)

European HTA bodies have signaled that they want greater and earlier dialogue with pharma but is their call being answered?
Access and Evidence

Value: A Balancing Act

Ross Davies, (Oct 16, 2018)

When it comes to proving the value of a new medicine, pharma has to strike the right balance
Access and Evidence

Can Payers Trust Our Data?

Andy stone, (Oct 16, 2018)

Analyses from RWD are playing an increasingly important role, but will payers accept pharma’s figures?
Access and Evidence

Diving for Data

Andy stone, (Oct 16, 2018)

Finding the right data to underpin outcome-based contracts is not as easy as it looks

Pages